---

Seleccionando la terapia más adecuada para cada paciente con TNE pancreáticos

1

PROGRESS IN THE LAND OF NENS

2

ADVANCED NETS – THERAPEUTIC ALGORITHM

3

Número de diapositiva 4

4

Número de diapositiva 5

5

Número de diapositiva 6

6

SUNITINIB VS PLACEBO IN ADVANCED PNET

7

Número de diapositiva 8

8

STZ-BASED CHEMOTHERAPY IN PNETS

9

THERAPEUTIC ALGORITHM FOR panNETS

10

CLINIC-PATHOLOGICAL CRITERIA

11

CAN WE REALLY SELECT PTS ?

12

LOCOREGIONAL LIVER-DIRECTED THERAPIES:RETROSPECTIVE / NON-RCT

13

PRRT FOR SSTR1-5 POSITIVE TUMORS:BUT ONLY PHASE III DATA IN SI-NETS

14

BETTER KNOWLEDGE OF MOLECULAR BIOLOGY MEANS BETTER PATIENTS’ SELECTION ?

15

BETTER KNOWLEDGE OF MOLECULAR BIOLOGY MEANS BETTER PATIENTS’ SELECTION ?

16

CHEMOTHERAPY PREDICTIVE BIOMARKER

17

PROGNOSTIC VALUE OF MTOR PATHWAY ACTIVATION IN NETS

18

PREDICTIVE VALUE OF MTOR PATHWAY ACTIVATION IN NETS

19

BETTER KNOWLEDGE OF MOLECULAR BIOLOGY MEANS BETTER PATIENTS’ SELECTION ?

20

Número de diapositiva 21

21

SUGGESTED CHEMOTHERAPY IN FIRST-LINE REGARDING NEW CLASSIFICATION

22

Growing evidence for TT in G3 (NET>NEC)

23

CAN WE REALLY SELECT PTS ?

24

Número de diapositiva 25

25

Número de diapositiva 26

26

Número de diapositiva 27

27

Número de diapositiva 28

28

Número de diapositiva 29

29

RECIST vs CHOI EXPERIENCE WITH SUNITINIB IN THE PHASE III STUDY

30

CAN WE REALLY SELECT PTS ?

31

THERAPEUTIC ALGORITHM FOR panNETS

32

EVEROLIMUS IS CLINICALLY BENEFICIAL REGARDLESS OF PRIOR CHEMOTHERAPY USE

33

EFFICACY MAY DECREASE OVER TREATMENT LINES

34

ACADEMIC GETNE PHASE III SEQUENTIAL TRIAL

35

TAKE HOME MESSAGES

36

Gracias !

37